Research graph
References from Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
10.1182/blood-2013-03-491514 · 2013 · External reference
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study
10.1200/jco.19.01073 · 2019 · External reference
Obinutuzumab for the first-line treatment of follicular lymphoma
10.1056/nejmoa1614598 · 2017 · External reference
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
10.1200/jco.18.00400 · 2019 · External reference
Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era
10.1038/s41375-022-01535-y · 2022 · External reference
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
10.1016/s2352-3026(18)30090-5 · 2018 · External reference
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma
10.1182/blood.2019000258 · 2019 · External reference
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
10.1200/jco.2015.65.7163 · 2016 · External reference
Risk factors for and outcomes of follicular lymphoma histological transformation at first progression in the GALLIUM study
10.1016/j.clml.2022.09.003 · 2023 · External reference
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
10.1111/bjh.12570 · 2013 · External reference
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
10.1111/bjh.14831 · 2017 · External reference
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic specialized program of research excellence molecular epidemiology resource
10.1200/jco.2012.48.3990 · 2013 · External reference
Robust prognostic value of histologic transformation in patients with early progression of follicular lymphoma
10.1080/10428194.2023.2226429 · 2023 · External reference
Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials
10.1200/jco.2016.70.8651 · 2017 · External reference
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
10.1002/ajh.24492 · 2016 · External reference
Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study
10.1200/jco.2014.59.7534 · 2015 · External reference
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
10.1182/blood.2020010263 · 2022 · External reference
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
10.3324/haematol.2019.230649 · 2020 · External reference
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
10.1016/j.annonc.2023.10.121 · 2024 · External reference
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
10.1016/s1470-2045(18)30102-5 · 2018 · External reference
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
10.1182/blood-2016-05-717355 · 2016 · External reference
Follicular lymphoma evaluation index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy
10.1002/ajh.25973 · 2020 · External reference
Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial
10.1002/hon.2437_85 · 2017 · External reference
FLIPI24: an improved international prognostic model developed on early events in follicular lymphoma
10.1182/blood-2022-157194 · 2022 · External reference
Randomized phase II trial in early relapsing or refractory follicular lymphoma (NCT#03269669): SWOG S1608
10.1182/blood-2021-146182 · 2021 · External reference
Histological transformation and progression in follicular lymphoma: a clonal evolution study
10.1371/journal.pmed.1002197 · 2016 · External reference
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
10.1200/jco.2005.12.072 · 2005 · External reference
Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies
10.1200/jco.2016.66.9440 · 2016 · External reference
Impact of early histological transformation on survival in patients with follicular lymphoma
10.1182/blood-2023-190325 · 2023 · External reference
10.3109/10428194.2013.770151
10.3109/10428194.2013.770151 · 2013 · External reference
